<p>2025 年 10 月 8 日- 下午 04:57</p>
<p><em>Navidea Biopharmaceuticals, Inc.申请破产</em></p>
<p>俄亥俄州哥伦布市 --（商业新闻）--Navidea Biopharmaceuticals, Inc.（“Navidea” 或 “公司”）是一家专注于精准免疫诊断剂和免疫治疗药物开发的生物制药公司，今天宣布于 2025 年 10 月 1 日在特拉华州美国破产法院（“法院”）根据美国破产法第 11 章第 V 小节提交了自愿破产申请。</p>
<p>该申请旨在使公司能够在继续有限运营以保护债权人和利益相关者的价值的同时，有序重组其财务义务。公司打算利用第 11 章程序评估战略选择，保护其资产，并确保对债权人的公平对待。</p>
<p><strong>获取案件信息</strong></p>
<p>Epiq Corporate Restructuring, LLC（“Epiq”）担任公司第 11 章案件的索赔和通知代理。债权人、股东和其他相关方可以通过访问 Epiq 网站获取有关案件的更多信息，包括法院文件、索赔表格和关键日期，网址为：https://dm.epiq11.com/Navidea。此外，债权人、股东和其他相关方可以在案件网站上注册，以免费接收所有已登记法院诉状的电子副本。</p>
<p><strong>关于 Navidea</strong></p>
<p>Navidea Biopharmaceuticals, Inc.是一家专注于精准免疫诊断剂和免疫治疗药物开发的生物制药公司。Navidea 正在基于其 Manocept 平台开发多种精准靶向产品，以通过识别疾病的部位和途径来增强患者护理，并提高诊断准确性、临床决策和靶向治疗。Navidea 的 Manocept 平台基于能够特异性靶向在活化巨噬细胞上表达的 CD206 甘露糖受体的能力。Manocept 平台作为 Tc99m tilmanocept 的分子基础，这是 Navidea 基于该平台开发和商业化的第一个产品。Navidea 的战略是通过其多样化的美国和外国专利及专利申请组合，市场化新产品并推进公司的产品管道，通过全球合作和商业化努力。有关更多信息，请访问 www.navidea.com。</p>
<p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTEwMDg4NDM4MzlyMQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTEwMDg4NDM4MzlyMQ"/></p>
<p>在 businesswire.com 查看源版本：https://www.businesswire.com/news/home/20251008843839/en/</p>
<p>首席财务官 Craig A. Dais</p>
<p>cdais@navidea.com</p>
<p>(614)-822-2322</p>
<p>来源：Navidea Biopharmaceuticals, Inc.</p>

NAVBQ

<p>Navidea Biopharmaceuticals, Inc. 于 2025 年 10 月 1 日在特拉华州美国破产法院申请了第 11 章破产。该公司旨在重组其财务义务，同时继续有限的运营，以为债权人和利益相关者保留价值。Navidea 专注于开发精准免疫诊断剂和免疫治疗药物，利用其 Manocept 平台提高诊断准确性和治疗效果。Epiq Corporate Restructuring, LLC 正在管理该破产案件，为债权人和相关方提供信息</p>

<p>10/08/2025 - 04:57 PM</p>
<div class="lb-trans"><p>2025 年 10 月 8 日- 下午 04:57</p>
</div><p><em>Navidea Biopharmaceucitals, Inc. files for Bankruptcy</em></p>
<div class="lb-trans"><p><em>Navidea Biopharmaceuticals, Inc.申请破产</em></p>
</div><p>COLUMBUS, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (“Navidea” or the “Company”), a biopharmaceutical company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that it filed a voluntary petition for relief under Chapter 11, Subchapter V of the United States Bankruptcy Code in the U.S. Bankruptcy Court for the District of Delaware (the “Court”) on October 1, 2025.</p>
<div class="lb-trans"><p>俄亥俄州哥伦布市 --（商业新闻）--Navidea Biopharmaceuticals, Inc.（“Navidea” 或 “公司”）是一家专注于精准免疫诊断剂和免疫治疗药物开发的生物制药公司，今天宣布于 2025 年 10 月 1 日在特拉华州美国破产法院（“法院”）根据美国破产法第 11 章第 V 小节提交了自愿破产申请。</p>
</div><p>The filing is intended to enable the Company to pursue an orderly restructuring of its financial obligations while continuing limited operations to preserve value for creditors and stakeholders. The Company intends to use the Chapter 11 process to evaluate strategic alternatives, protect its assets, and ensure fair treatment of creditors.</p>
<div class="lb-trans"><p>该申请旨在使公司能够在继续有限运营以保护债权人和利益相关者的价值的同时，有序重组其财务义务。公司打算利用第 11 章程序评估战略选择，保护其资产，并确保对债权人的公平对待。</p>
</div><p><strong>Access to Case Information</strong></p>
<div class="lb-trans"><p><strong>获取案件信息</strong></p>
</div><p>Epiq Corporate Restructuring, LLC (“Epiq”) is serving as the claims and noticing agent for the Company’s Chapter 11 case. Creditors, shareholders, and other interested parties can obtain additional information about the case, including court filings, claim forms, and key dates, by visiting the Epiq website at: https://dm.epiq11.com/Navidea. Additionally, creditors, shareholders, and other interested parties can register on the case website to receive electronic copies of to all docketed Court pleadings, free of charge.</p>
<div class="lb-trans"><p>Epiq Corporate Restructuring, LLC（“Epiq”）担任公司第 11 章案件的索赔和通知代理。债权人、股东和其他相关方可以通过访问 Epiq 网站获取有关案件的更多信息，包括法院文件、索赔表格和关键日期，网址为：https://dm.epiq11.com/Navidea。此外，债权人、股东和其他相关方可以在案件网站上注册，以免费接收所有已登记法院诉状的电子副本。</p>
</div><p><strong>About Navidea</strong></p>
<div class="lb-trans"><p><strong>关于 Navidea</strong></p>
</div><p>Navidea Biopharmaceuticals, Inc. is a biopharmaceutical company focused on the development of precision immunodiagnostic agents and immunotherapeutics. Navidea is developing multiple precision-targeted products based on its Manocept platform to enhance patient care by identifying the sites and pathways of disease and enable better diagnostic accuracy, clinical decision-making, and targeted treatment. Navidea’s Manocept platform is predicated on the ability to specifically target the CD206 mannose receptor expressed on activated macrophages. The Manocept platform serves as the molecular backbone of Tc99m tilmanocept, the first product developed and commercialized by Navidea based on the platform. Navidea’s strategy is to market novel products and advancing the Company’s pipeline through global partnering and commercialization efforts through its diverse portfolio of issued US and foreign patents and patent applications. For more information, visit www.navidea.com.</p>
<div class="lb-trans"><p>Navidea Biopharmaceuticals, Inc.是一家专注于精准免疫诊断剂和免疫治疗药物开发的生物制药公司。Navidea 正在基于其 Manocept 平台开发多种精准靶向产品，以通过识别疾病的部位和途径来增强患者护理，并提高诊断准确性、临床决策和靶向治疗。Navidea 的 Manocept 平台基于能够特异性靶向在活化巨噬细胞上表达的 CD206 甘露糖受体的能力。Manocept 平台作为 Tc99m tilmanocept 的分子基础，这是 Navidea 基于该平台开发和商业化的第一个产品。Navidea 的战略是通过其多样化的美国和外国专利及专利申请组合，市场化新产品并推进公司的产品管道，通过全球合作和商业化努力。有关更多信息，请访问 www.navidea.com。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTEwMDg4NDM4MzlyMQ" alt="" original-src="https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20251008843839r1&amp;sid=acqr8&amp;distro=nx&amp;lang=en"/></p>
<p>View source version on businesswire.com: https://www.businesswire.com/news/home/20251008843839/en/</p>
<div class="lb-trans"><p>在 businesswire.com 查看源版本：https://www.businesswire.com/news/home/20251008843839/en/</p>
</div><p>Craig A. Dais, Chief Financial Officer</p>
<div class="lb-trans"><p>首席财务官 Craig A. Dais</p>
</div><p>cdais@navidea.com</p>
<div class="lb-trans"><p>cdais@navidea.com</p>
</div><p>(614)-822-2322</p>
<div class="lb-trans"><p>(614)-822-2322</p>
</div><p>Source: Navidea Biopharmaceuticals, Inc.</p>
<div class="lb-trans"><p>来源：Navidea Biopharmaceuticals, Inc.</p>
</div>

Navidea Biopharmaceuticals, Inc.申请破产保护 | NAVB 股票新闻